Analyzing Gene Expression in Lung Adenocarcinoma
back to Lung Adenocarcinoma main page
References
1 Ahrendt et al, J Natl Cancer Inst, 2003: “p53 mutations and survival in Stage I non-small-cell lung cancer: Results of a prospective study”
2 Yeatman, Ann Surg Oncol, Jan-Feb 2003: “The future of cancer management: translating the genome, transcriptome, and proteome”; Coppola et al, Clin Cancer Res, Jan 2004: “Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies”
3 Thomas et al, Journal of Pathology, Feb 2000: “Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer”; Shou et al, British Journal of Cancer, Nov 2001: “Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer”; Bodey et al, In Vivo, Mar-Apr 2001: “Invasion and metastasis: The expression and significance of matrix metalloproteinases in carcinomas of the lung”; Yamamura et al, Lung Cancer, Mar 2002: “Expression of membrane-type-1 matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas”
4 HY Lee et al, Cancer Res, June 2002: "Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer“; Beer et al, Nature Medicine, Aug 2002: “Gene-expression profiles predict survival of patients with lung adenocarcinoma”
5 S Morita et al, Int J Cancer, Oct 1998: "Cancer cells overexpress mRNA of urokinase-type plasminogen activator, its receptor and inhibitors in human non-small-cell lung cancer tissue: analysis by Northern blotting and in situ hybridization"
6 Manegold et al, Investigational New Drugs, 2000: “Gemcitabine in non-small cell lung cancer (NSCLC)”; Heighway et al: expression of human Rr2 [RRM2] mRNA occurs in human non-small-cell lung carcinoma
7 G Feng et al, Cancer Res, Nov 2001: "Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis“
8 V Zabrenetzky et al, Int J Cancer, Oct 1994: "Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines“; Vailhe, Curr Pharm Des, 2003: evaluated as anti-tumorigenic agent; Streit, Cancer Res, Apr 2002: “Systemic inhibition of tumor growth and angiogenesis by thrombospondin-2 using cell-based antiangiogenic gene therapy”; Hawighorst et all, EMBO Journ, June 2001: “Thrombospondin-2 plays a protective role in multistep carcinogenesis: A novel host anti-tumor defense mechanism”